Exogenous Hormone Use and the Risk of Postmenopausal Breast-cancer - Results From the Netherlands Cohort Study

The association between the use of exogenous hormones as either oral contraceptives (OC) or hormone replacement therapy (HRT) in relation to postmenopausal breast cancer incidence was examined in the Netherlands Cohort Study (NLCS) among 62,573 women aged 55 to 69 years. Information on these types of exogenous hormone use and other risk factors was collected by mailed questionnaire. During 3.3 years of followup, 471 incident breast cancer cases were identified After adjustment for traditional breast cancer risk factors, the relative risk (RR) of breast cancer was 1.09 (95 percent confidence interval [CI] = 0.79-1.48) for women who ever used OCs cf women who never used OCs. The relative rates (with CIs) for women who used OCs for a period <5 years, 5-9 years, 10-14 years, and 15+ years were 0.97 (0.61-1.55), 1.20 (0.69-2.07), 1.03 (0.60-1.77), and 1.96 (0.99-3.89), respectively. The test for trend was not significant (P = 0.13). There was no evidence of any association between the number of years between the first and the last use of OCs and breast cancer incidence. In the subgroup of women with first-degree relatives with breast cancer, the RR for breast cancer associated with ever use of OCs was 1.51 (CI = 0.67-3.41), whereas in the remaining women, the RR was 0.97 (CI = 0.73-1.27). Ever-use of HRT compared with never-use was not associated with an increase in breast cancer risk in the multivariate analysis (RR = 0.99, CI = 0.68-1.43). Also, the number of years of HRT use was not associated with an increased breast cancer risk (trend P = 0.83), nor was the number of years between the first and the last use of HRT and breast cancer incidence. One subgroup of women in which the use of HRT seemed associated (but not significantly) with an increase in breast cancer risk was women with an induced menopause (RR = 1.72, CI = 0.95-3.12). The RR of breast cancer for women who had ever used both OCs and HRT, compared with women who never used these exogenous hormones was 1.00 (CI = 0.51-1.94). From this study, it cannot be concluded that the use of exogenous hormones is a strong risk factor for the development of postmenopausal breast cancer.